La cadena de opciones muestra datos clave de las opciones de acciones de Cognyte Software a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cognyte Software..

Cognyte Software (NASDAQ:CGNT) Bolsa, Cadena de Opciones

Cognyte Software

Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.

Cognyte Software Ltd

<ul>
<li>Northstrive Biosciences and Yuva Biosciences previously announced a collaboration leveraging MitoNova&#x2122;, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.</li>
<li>Phase II of this collaboration involves compiling a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases.</li>
</ul>
NEWPORT BEACH, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) (the "Company," "PMGC," "we," or "our"), today announced the initiation of Phase II of the AI Development Program with strategic partner Yuva Biosciences, Inc. ("YuvaBio"). As part of the Phase II objective, both companies will collaborate to leverage MitoNova&#x2122;, YuvaBio's AI mitochondrial science-focused artificial intelligence platform, to compile a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases.
YuvaBio will use MitoNova&#x2122; to virtually screen a large-scale library of diverse, drug-like small molecules and predict which candidates are most likely to promote mitochondrial health. YuvaBio will then analyze results of this screen, including chemical and bioactivity properties, to highlight opportunities for biological validation. Then, YuvaBio will compile an initial list of synthetic compounds for muscle preservation and metabolic health.

News

ELAB

Northstrive Biosciences Initiates Phase II Of AI Development Program With Strategic Partner Yuva Biosciences

Travel

General

JBLU

CNBC: 'JetBlue to cut more flights, other costs with break-even 2025 'unlikely' due to weaker travel demand'

ATLN

Atlantic International Announces It Has Been Added As A Member Of The Broad-Market Russell 3000 Index, Effective After The U.S. Market Opens On June 30, 2025

Barclays analyst Brandt Montour maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Overweight and raises the price target from $26 to $30.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Carnival, Raises Price Target to $30

AIRJ

AirJoule Technologies Signs MOU With A Developer Of Hyperscale Data Centers To Collaborate On Use Of AirJoule Technology

iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) ("iPower" or the "Company"), a technology-driven eCommerce and supply chain platform, today announced a major strategic shift approved by its Board of Directors. The Company intends to reposition itself as a&nbsp;crypto treasury and blockchain infrastructure services company, with an initial and central emphasis on building a&nbsp;Bitcoin treasury strategy&nbsp;as a foundational component of its future growth.
As part of this transformation, iPower intends to start accumulating&nbsp;Bitcoin as a treasury reserve asset, with the aim of creating a long-term store of value and serving as a key element in enhancing iPower's financial resilience and strategic optionality.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

iPower Shifts Strategy To Focus On Bitcoin Treasury And Blockchain Infrastructure Services

Barclays analyst Tom O'Malley maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and raises the price target from $170 to $200.

NVDA

Barclays Maintains Overweight on NVIDIA, Raises Price Target to $200

Offerings

RBNE

Robin Energy Announces Registered Direct Offering Of 965K Common Shares At An Offering Price Of $5.25

WIIM

PCSA

Processa Pharmaceuticals shares are trading higher after the company signed a binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 for gastroparesis.

IZEA

IZEA Worldwide Announces Preliminary Results Of Dutch Auction Tender Offer, Repurchasing $8.7M In Shares At $2.80/Shr

The cryptocurrency market pulled back Tuesday morning, driven by heightened geopolitical concerns following Trump's evacuation warning regarding the <a href="https://www.benzinga.com/news/politics/25/06/45965629/trump-exits-g7-summit-early-citing-obvious-reasons-amid-escalating-iran-israel-conflict-gold-oil-etfs-spike-in-after-hours-trading">Iran-Israel conflict</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$105,869.34</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,551.61</td>
<td>-2.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$150.97</td>
<td>-3.2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.21</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1715</td>
<td>-2.9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001172</td>
<td>-3.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows that Bitcoin and Ethereum&#8217;s large transaction volumes increased 116.4% and 189.5%, respectively. Also, BTC&#8217;s daily active addresses witnessed a growth of 18.1%. Ethereum exchanges&#8217; net flows widened by 4,988.5% in a single day.</li>
<li>Coinglass data shows 104,900 traders were liquidated in the past 24 hours with the total liquidations at $354.58 million.</li>
<li>SoSoValue data shows net inflows of $412.2 million into spot Bitcoin ETFs while Spot Ethereum ETFs saw net inflows of $21.4 million.</li>
</ul>
Trader Notes: Crypto trader Jelle noted that the past two Bitcoin cycles lasted 1,064 days from bottom to top. If that pattern continues, we're now entering the final 18-week stretch, potentially marking the most profitable phase. The best gains may still lie ahead.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The previous complete cycles both lasted 1064 days, from the bottom to the top. If that pattern repeats, we have 18 weeks of fun ahead. The most profitable part of the cycle is ahead. Godspeed brothers. <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/x5ENwINIqR">pic.twitter.com/x5ENwINIqR</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1934885956550627598?ref_src=twsrc%5Etfw">June 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Jelle also <a href="https://x.com/CryptoJelleNL/status/1934909062443094100">pointed</a> out that Bitcoin has confirmed a monthly breakout and retest, a classic signal of trend continuation.
For Ethereum, Galaxy <a href="https://x.com/galaxyBTC/status/1934820005683564835">highlighted</a> Ethereum's current monthly setup, which mirrors patterns seen at the start of past bull runs. Another trader, Hardy, reaffirmed his long-entry zone around $2,180, citing strong macro support and technical confluence.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> UPDATE &#x1f4ca; Pland remains the same folks, zone of interest and my ideal zone to LONG is 2,180. Its got confluence and a macro support for this range. <a href="https://t.co/Sin0uMKh7I">pic.twitter.com/Sin0uMKh7I</a>
&mdash; Hardy (@Degen_Hardy) <a href="https://twitter.com/Degen_Hardy/status/1934916670298182045?ref_src=twsrc%5Etfw">June 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Brett <a href="https://x.com/Brett_Crypto_X/status/1934910647663538438">sees</a> XRP forming a bullish pennant on the weekly chart after a 486% surge, a textbook continuation pattern. A breakout above $2.40 could potentially lead to another 500% upside.
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1934903868917469526">noted</a> that Dogecoin has formed a falling wedge pattern on the 4-hour chart, a bullish reversal structure. As the price nears the wedge apex, bearish pressure appears to be fading.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/45967028/max-keiser-once-predicted-bitcoin-could-hit-a-300-trillion-market-cap-heres-how-much-1-btc-would-be-worth-if-that-happens">Max Keiser Once Predicted Bitcoin Could Hit A $300 Trillion Market Cap — Here&#8217;s How Much 1 BTC Would Be Worth If That Happens </a></li>
</ul>
Photo: alfernec on Shutterstock.com

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, Dogecoin Drop As Geopolitical Tensions Escalate

<a href="https://www.globenewswire.com/Tracker?data=efyyNC6NBz6Y2CBUFC-ZYhXNItGJecUidi50lQJv-4qiMfqYN3tpCfe8CIwoI0jJ3FRIlnIPd2E7y-ns3hZiDpLIQ8as0qz_tQD_iUHltY4=">Varonis Systems, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>), the data security leader, today extended its industry-leading Data Security Platform to OpenAI's ChatGPT Enterprise Compliance API. The integration helps customers automatically identify sensitive data uploads, monitor prompts and responses, and prevent breaches and compliance violations.
ChatGPT Enterprise boosts workforce productivity for <a href="https://www.globenewswire.com/Tracker?data=10KtUbL7-LoNnWDEOHdyUby-txGffWT62Zd6qGNwfayVJ9aEF802cuvQM8A7D8VrXl_qg9Z1ebIQb4brm7LVkoelCYRJCUGBc1OP1DjNBryJ8t69h-RtDYYZal6ZUTW4TxUtVsa0YeIPBZ-dTnH0LSEWMJC4mURNmOTlB5lZH1_IKftfJLTRdB8FXC2kEER4">more than 3 million enterprise users.</a> The more data the application can access, the more relevant and useful its responses become.
Varonis for ChatGPT Enterprise gives customers a powerful and additional layer of defense against compromised accounts, insider threats, and misuse that could result in data breaches or regulatory penalties. By continuously right-sizing permissions and monitoring interactions, Varonis limits sensitive data flows and alerts security teams to abnormal and risky behavior.

VRNS

Varonis Integrates Data Security Platform With OpenAI's ChatGPT Enterprise Compliance API To Enhance Data Protection And Compliance

CAPR

Capricor Therapeutics Granted Orphan Drug Designation For Deramiocel In Becker Muscular Dystrophy

Macro Economic Events

Econ #s

Economics

CORRECTION: USA Redbook (YoY) 5.2% Vs 4.7% Prior

OMDA

Omada Health Releases New Data Demonstrating Omada's GLP-1 Companion Program Improved Persistence Rates For GLP-1 Medications

Under Agreement, Processa Pharmaceuticals Is Eligible To Receive $2.5M Option Exercise Fee And $452.5M In Total Milestones

Johnson Rice analyst Martin Malloy initiates coverage on Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy rating and announces Price Target of $20.

Initiation

Johnson Rice Initiates Coverage On Venture Global with Buy Rating, Announces Price Target of $20

Processa Pharmaceuticals Signs Binding Term Sheet With Intact Therapeutics, Granting Intact The Exclusive Option To License PCS12852 In Gastroparesis

4 analysts have expressed a variety of opinions on Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.75, a high estimate of $18.00, and a low estimate of $12.00. This current average represents a 4.1% decrease from the previous average price target of $15.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1750165255_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Riot Platforms among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Riot Platforms. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Riot Platforms compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Riot Platforms's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Riot Platforms's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RIOT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Riot Platforms analyst ratings.</a>
<h2>All You Need to Know About Riot Platforms</h2>
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.
<h3>Riot Platforms: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Riot Platforms showcased positive performance, achieving a revenue growth rate of 103.52% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -183.64%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Riot Platforms's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.74%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Riot Platforms's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.74%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Riot Platforms's debt-to-equity ratio is below the industry average. With a ratio of 0.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RIOT

4 Analysts Assess Riot Platforms: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $93.0, a high estimate of $105.00, and a low estimate of $76.00. A 14.52% drop is evident in the current average compared to the previous average price target of $108.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1750165243_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cooper Companies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cooper Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Cooper Companies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Cooper Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>About Cooper Companies</h2>
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
<h3>Unraveling the Financial Story of Cooper Companies</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Cooper Companies's revenue growth over a period of 3M has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 6.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cooper Companies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cooper Companies's ROE stands out, surpassing industry averages. With an impressive ROE of 1.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.71%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Cooper Companies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Cooper Companies Stock

Press Releases

Cognyte 2025 Threat Landscape Report Reveals Global Trends in Cyberattacks, Ransomware and Stolen Credentials

APAC Law Enforcement Agency Invests $5+ Million in Cognyte to Strengthen Public Safety

Small Cap

COPPER GIANT EXTENDS THE MOCOA COPPER PORPHYRY EAST, INTERSECTING COPPER MINERALIZATION IN ZONES PREVIOUSLY MODELLED AS WASTE

Cognyte to Participate in 20th Annual Needham Technology & Media Conference

Cognyte Secures ~$5 Million Contract with New Law Enforcement Agency Customer in EMEA

Cognyte to Participate in 53rd Annual TD Cowen Technology, Media and Telecom Conference

Cognyte Secures $10+ Million Annual 3-Year Subscription Agreement with National Security Agency

Comments

Cognyte Software

Cognyte Software (CGNT) Opciones

Cognyte Software (NASDAQ:CGNT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL